(85 days)
Not Found
No
The device description and performance studies focus on the physical characteristics and mechanical performance of the catheter, with no mention of AI or ML.
Yes
The device is intended for the administration of local anesthetics to provide continuous epidural caudal anesthesia, which is a therapeutic intervention to alleviate pain.
No
The device description and intended use clearly state that the AMT NanoCath is an epidural catheter for administering local anesthetics, which is a therapeutic function, not a diagnostic one.
No
The device description clearly outlines physical components made of stainless steel, polyethylene terephthalate, delrin, and polycarbonate, indicating it is a hardware device.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use is for the administration of local anesthetics into the epidural space. This is a therapeutic procedure performed directly on a patient's body.
- Device Description: The description details a physical catheter designed for insertion into the body.
- Lack of IVD Characteristics: There is no mention of the device being used to examine specimens derived from the human body (like blood, urine, tissue, etc.) to provide information for diagnosis, monitoring, or compatibility testing.
IVD devices are used outside the body to analyze samples and provide diagnostic information. This device is used inside the body for a therapeutic purpose.
N/A
Intended Use / Indications for Use
The AMT NanoCath™ epidural catheter is intended for administration of local anesthetics into the epidural space to provide continuous epidural caudal anesthesia for up to 72 hours
Product codes
BSO
Device Description
The AMT NanoCath is comprised of a tightly coiled stainless steel, covered over most of its length with polvethylene terphthalate. The tip of the catheter is welded into a smooth cover to which is welded a safety ribbon of stainless steel. A stylet of stainless with a plastic handle made of delrin or polycarbonate fits inside the catheter. The catheter is available in 19 - 21 gauge, in lengths of 30 to 90 cm. The wire coil has an outer diameter from 0.8 to 1.0 mm. The NanoCath was compared with substantially equivalent devices in fatigue tests and shown equivalent.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
epidural space
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
The NanoCath was compared with substantially equivalent devices in fatigue tests and shown equivalent.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s)
K023140, K981329, K042488, K033952, K991879, K954584
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 868.5120 Anesthesia conduction catheter.
(a)
Identification. An anesthesia conduction catheter is a flexible tubular device used to inject local anesthetics into a patient and to provide continuous regional anesthesia.(b)
Classification. Class II (performance standards).
0
MAY 2 7 2005
XIV. 510(k) SUMMARY OF SAFETY AND EFFECTIVENESS DATA. (Separate Pages)
- A. Submitter: Michael Renick, American Medical Technologies, 1211 West 13th St. Rivera Beach, Fl. 33404. Phone: 561-818-0625.
I. Classification Name and Number: Catheter, Conduction, Anesthetic, Class II, BSO
II. Common/Usual Name: Epidural catheter
III. Proprietary Name: AMT NanoCath™
III.1. Registration No: in process
IV. Classification: This device was classified by the U. S. Food and Drug Administration Anesthesiology Devices Panel (Title 21 Code of Federal Regulations, Part 868.5120). The FDA Classification "Number" is BSO; the product is in Class II,
V. Performance Standards: None applicable. Surgical stainless steel meets ASTM A276 and A479 for the 304 or 316 stainless steel. The coating meets USP Class VI and ISO 10993 for biocompatibility.
VI. Description: The AMT NanoCath is comprised of a tightly coiled stainless steel, covered over most of its length with polvethylene terphthalate. The tip of the catheter is welded into a smooth cover to which is welded a safety ribbon of stainless steel. A stylet of stainless with a plastic handle made of delrin or polycarbonate fits inside the catheter. The catheter is available in 19 - 21 gauge, in lengths of 30 to 90 cm. The wire coil has an outer diameter from 0.8 to 1.0 mm. The NanoCath was compared with substantially equivalent devices in fatigue tests and shown equivalent.
VI. Substantial Equivalence: The AMT NanoCath™ is substantially equivalent to the Versa-Kath Epidural Catheter cleared by Epimed in K023140, has the same use, and was subjected to similar bench testing which confirmed that the performance is equivalent, The NanoCath™ is also equivalent to the Feth-R-Cath cleared by Epimed in K981329. It is manufactured very similarly to the Perifix FX by Braun (several 510(k)s, e.g.K042488, K033952) and is equivalent to this device. The AMT NanoCath™ is substantially equivalent as well to older epidural catheters such as the Spring-Wound Epidural Catheter cleared by Micor in K991879 and the Racz Epidural Catheter cleared in K954584.
(cont'd)
1
The NanoCath also is manufactured very similarly to the Perifix FX by Braun (several 510(k)s, e.g. K042488, K033952) and is equivalent to this device. The AMT NanoCath™ is substantially equivalent as well to older epidural catheters such as the Spring-Wound Epidural Catheter cleared by Micor in K991879 and the Racz Epidural Catheter cleared in K954584.
Characteristics of the materials used in the AMT NanoCath™ and in many of the current substantially equivalent devices are shown in Appendix IV.
The "510(k) "Substantial Equivalence" Decision-Making Process (Detailed) from ODE Guidance Memorandum #86-3 was followed as described below:
-
- These products have the same intended use, to administer anesthetic agents into the epidural space to provide continuous epidural or caudal anesthesia for up to 72 hours.
-
- The technological characteristics for this product are similar to those for the predicate devices and those currently on the market which have some differences in technology but the technological differences are well understood in the anesthetic industry so substantial equivalence in safety and effectiveness is assured.
-
- The materials from which this device is made are well-established in the industry and are used in predicate devices.
-
- The FDA "Decision-Making Process" chart was used and appears in Attachment V.
2
Image /page/2/Picture/1 description: The image shows a circular seal with the logo of the U.S. Department of Health and Human Services (HHS). The seal features the HHS emblem, which is a stylized depiction of an eagle with three lines representing its wings. The text "U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, INC." is arranged around the perimeter of the circle.
MAY 2 7 2005
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
Mr. Michael Renick President American Medical Technologies, Incorporated 1211 West 13th Street Riviera Beach, Florida 33404
Re: K050557
Trade/Device Name: AMT NanoCath™ Regulation Number: 21 CFR 868.5120 Regulation Name: Anesthesia Conduction Catheter Regulatory Class: II Product Code: BSO Dated: February 12, 2005 Received: March 3, 2005
Dear Mr. Renick:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
3
Page 2 - Mr. Renick
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0120. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.
Sincerely yours,
Chiu Lin, Ph.D.
Director Division of Anesthesiology, General Hospital, Infection Control and Dental Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
4
Indications for Use
510(k) Number (if known): K050557
Device Name: AMT NanoCath™
Indications For Use:
The AMT NanoCath™ epidural catheter is intended for administration of local anesthetics into the epidural space to provide continuous epidural caudal anesthesia for up to 72 hours
Prescription Use X (Per 21 CFR 801.109) OR
Over-The-Counter Use (21 CFR 801 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Evaluation (ODE)
Clu
(Division Sign-Off) Division of Anesthesiology, General Hospital, Infection Control. Dental Devices
510(k) Number. K052537
Page 1 of 1 Repl. p. 6